Physician profile
Morgan Holmes
NPI 1982218186
$1,329.73
in general payments reported to CMS, 2019-2025
24 companies · $260 in 2025
The $260 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $361 · 2022: $222 · 2023: $174 · 2024: $313 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $746.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $284.88 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $150.97 | 2021-2024 | |
| Misonix INC | $124.99 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.25 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $74.25 | 2021-2025 | Airsupra, Breztri |
| Novo Nordisk INC | $70.32 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Xeris Pharmaceuticals, INC. | $69.23 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Lundbeck LLC | $49.54 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $44.79 | 2022 | |
| Astellas Pharma US INC | $42.66 | 2024-2025 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $35.71 | 2023-2024 | Eliquis, Camzyos |
| Glaxosmithkline, LLC. | $32.21 | 2023-2025 | Shingrix, Bexsero, Trelegy Ellipta |
| Sumitomo Pharma America, INC. | $29.84 | 2024 | Gemtesa |
| Inspire Medical Systems, INC. | $26.00 | 2025 | Inspire |
| Radius Health, INC. | $25.12 | 2024 | Tymlos |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $21.04 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.11 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.91 | 2022 | |
| Dexcom, INC. | $17.72 | 2025 | Dexcom G6 Transmitter |
| Ibsa Pharma INC. | $17.28 | 2023 | Tirosint, Licart |
| Merck Sharp & Dohme LLC | $16.52 | 2021 | |
| Daiichi Sankyo INC. | $15.49 | 2021 | |
| Corcept Therapeutics | $15.15 | 2023 | Korlym |
| Lilly USA, LLC | $13.75 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Holmes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.